Ligand Pharmaceuticals Incorporated (LGND): Price and Financial Metrics


Ligand Pharmaceuticals Incorporated (LGND): $140.73

0.22 (+0.16%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LGND to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

LGND POWR Grades


  • LGND scores best on the Growth dimension, with a Growth rank ahead of 76.18% of US stocks.
  • The strongest trend for LGND is in Value, which has been heading down over the past 48 weeks.
  • LGND ranks lowest in Stability; there it ranks in the 16th percentile.

LGND Stock Summary

  • Price to trailing twelve month operating cash flow for LGND is currently 53.67, higher than 91.38% of US stocks with positive operating cash flow.
  • Over the past twelve months, LGND has reported earnings growth of 2,313%, putting it ahead of 98.94% of US stocks in our set.
  • Revenue growth over the past 12 months for Ligand Pharmaceuticals Inc comes in at 99.11%, a number that bests 93.4% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Ligand Pharmaceuticals Inc are DCTH, CRNC, WATT, EH, and PI.
  • Visit LGND's SEC page to see the company's official filings. To visit the company's web site, go to www.ligand.com.

LGND Valuation Summary

  • LGND's EV/EBIT ratio is 46.3; this is 58.02% higher than that of the median Healthcare stock.
  • Over the past 243 months, LGND's price/sales ratio has gone down 0.9.
  • Over the past 243 months, LGND's price/sales ratio has gone down 0.9.

Below are key valuation metrics over time for LGND.

Stock Date P/S P/B P/E EV/EBIT
LGND 2021-08-31 8.8 2.8 46.1 46.3
LGND 2021-08-30 8.0 2.6 42.2 42.8
LGND 2021-08-27 7.6 2.4 39.8 40.7
LGND 2021-08-26 7.4 2.4 38.7 39.7
LGND 2021-08-25 7.5 2.4 39.5 40.4
LGND 2021-08-24 7.7 2.5 40.2 41.1

LGND Growth Metrics

  • Its year over year price growth rate is now at 22.75%.
  • Its 2 year price growth rate is now at -39.03%.
  • The 2 year cash and equivalents growth rate now stands at 130.34%.
LGND's revenue has moved up $9,336,000 over the prior 33 months.

The table below shows LGND's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 251.663 44.413 47.891
2021-03-31 208.408 48.418 39.252
2020-12-31 186.419 54.586 -2.985
2020-09-30 143.432 46.71 -16.111
2020-06-30 126.392 27.768 -24.661
2020-03-31 109.959 -57.672 -61.166

LGND's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LGND has a Quality Grade of C, ranking ahead of 61.05% of graded US stocks.
  • LGND's asset turnover comes in at 0.195 -- ranking 203rd of 677 Pharmaceutical Products stocks.
  • IRWD, MNKD, and BMRN are the stocks whose asset turnover ratios are most correlated with LGND.

The table below shows LGND's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.195 0.774 0.067
2021-03-31 0.162 0.837 0.054
2020-12-31 0.148 0.837 0.016
2020-09-30 0.111 0.856 0.006
2020-06-30 0.092 0.862 0.002
2020-03-31 0.073 0.889 -0.026

LGND Price Target

For more insight on analysts targets of LGND, see our LGND price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $207.00 Average Broker Recommendation 1.43 (Moderate Buy)

LGND Stock Price Chart Interactive Chart >

Price chart for LGND

LGND Price/Volume Stats

Current price $140.73 52-week high $219.75
Prev. close $140.51 52-week low $78.26
Day low $138.55 Volume 41,138
Day high $141.75 Avg. volume 329,364
50-day MA $123.15 Dividend yield N/A
200-day MA $133.55 Market Cap 2.35B

Ligand Pharmaceuticals Incorporated (LGND) Company Bio


Ligand Pharmaceuticals develops therapies that address the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. The company was founded in 1987 and is based in La Jolla, California.


LGND Latest News Stream


Event/Time News Detail
Loading, please wait...

LGND Latest Social Stream


Loading social stream, please wait...

View Full LGND Social Stream

Latest LGND News From Around the Web

Below are the latest news stories about Ligand Pharmaceuticals Inc that investors may wish to consider to help them evaluate LGND as an investment opportunity.

Ligand Pharmaceuticals Stock Shows Rising Price Performance

A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance.

Yahoo | September 22, 2021

Ligand Pharmaceuticals Stock Shows Market Leadership With Jump To 82 RS Rating

A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance.

Yahoo | September 20, 2021

Digital Turbine Stock Surges Set to Join S&P MidCap 400

The advertising name will replace Ligand Pharmaceuticals on Sept. 17

Schaeffers Investment Research | August 31, 2021

Performance Food Group & Digital Turbine Set to Join S&P MidCap 400; TreeHouse Foods & Ligand Pharmaceuticals to Join S&P SmallCap 600

S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600:

Yahoo | August 30, 2021

Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma

EMERYVILLE, Calif., August 30, 2021--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Gloria Biosciences (GloriaBio) has received approval from China’s National Medical Products Administration (NMPA) for zimberelimab (GLS-010), an OmniAb-derived anti-PD-1 monoclonal antibody for the treatment of recurrent or refractory classical Hodgkin’s lymphoma (cHL). GloriaBio has development and commercialization rights in China with respect to zimberelimab through a subli

Yahoo | August 30, 2021

Read More 'LGND' Stories Here

LGND Price Returns

1-mo 23.09%
3-mo 7.27%
6-mo -8.97%
1-year 46.98%
3-year -48.73%
5-year 37.96%
YTD 41.51%
2020 -4.64%
2019 -23.15%
2018 -0.90%
2017 34.76%
2016 -6.28%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9468 seconds.